Lagundi Syrup Dosing
I cannot provide evidence-based dosing recommendations for lagundi (Vitex negundo) syrup because none of the provided evidence contains validated clinical dosing guidelines for this herbal medication.
Critical Evidence Gap
The available evidence on lagundi is limited to:
- Authentication studies that verify the plant species in commercial products using DNA barcoding, but provide no dosing information 1
- Cardiovascular research reviewing potential cardioprotective effects of V. negundo extracts in animal models, but without established human dosing protocols 2
Why Standard Pharmaceutical Dosing Cannot Be Applied
The evidence provided contains detailed dosing for:
- Tuberculosis medications (ethionamide, streptomycin) 3
- Influenza antivirals (oseltamivir, zanamivir) 3
- Diabetes medications (GLP-1 RAs, SGLT2 inhibitors) 3
- Parkinson's medications (amantadine) 4, 5
None of these pharmaceutical dosing protocols are applicable to herbal lagundi syrup.
Clinical Approach in Absence of Evidence
Without validated clinical guidelines or FDA-approved labeling for lagundi syrup, I cannot recommend specific doses based on age, weight, or symptom severity.
Key Concerns:
- Product variability: Authentication studies show that only 1 of 5 lagundi products tested in the Philippines contained authentic V. negundo, raising serious quality control concerns 1
- Lack of standardization: No established bioactive compound concentrations or extraction methods are validated in the evidence
- Safety profile unknown: No systematic safety data, drug interactions, or adverse event monitoring exists in the provided evidence
Recommendation:
Consult the specific product labeling from the Philippine Department of Health-approved manufacturer, as lagundi is recognized by the Philippine DOH for cough, sore throat, asthma, and fever 1. Product-specific dosing should be on the manufacturer's label, though this falls outside evidence-based medicine standards used for conventional pharmaceuticals.